key: cord-0799085-oblw6kky
authors: Gurbel, Paul A.; Bliden, Kevin P.; Schrör, Karsten
title: Can an Old Ally Defeat a New Enemy?
date: 2020-06-01
journal: Circulation
DOI: 10.1161/circulationaha.120.047830
sha: debbff78a09062dd4c33cea1f88a9e76bde8b6b0
doc_id: 799085
cord_uid: oblw6kky

nan

of half-life and high (>90%) protein binding. Repetitive local dosing might result in higher and longer-lasting tissue levels of salicylate than seen from plasmatic levels. 1 The unique pharmacokinetic property of salicylate to accumulate in cell membranes may further promote tissue concentrations that inhibit viral replication.

We have recently studied inhaled nanoparticle ASA and demonstrated that it enters the circulation much faster and at greater levels than chewed and swallowed ASA. 4 We have estimated that the inhaled dose of LA-SAG required for adequate alveolar deposition (EC 50 , 3.9 mmol/L for Middle East respiratory syndrome coronavirus), assuming even distribution in the 36-mL lung lining fluid, is 51 mg. This dose is well below the cytotoxic dose. Therefore, on the basis of the tolerability of 10fold higher doses, we would propose a dose of 500 mg LASAG to effectively reduce the virus load in patients with severe acute respiratory syndrome coronavirus 2-infected lungs. Because this treatment targets a host cellular pathway, the chance that resistant virus variants would emerge is limited. As an adjunct to its direct antiviral property, patients may also benefit from proven analgesic and anti-inflammatory effects. Finally, a hypercoagulable state has been associated with adverse outcomes during COVID-19 infection. The antiplatelet effects of aspirin mediated by cyclooxygenase-1 inhibition may be expected, in part, to address this serious pathophysiology. Moreover, inhibition of thrombin formation will additionally support these anticoagulatory actions. 1 Finally, a new micronized aspirin tablet that is rapidly dissolving achieves peak plasma levels of unmetabolized ASA that are 3 times higher than standard formulations. With repeated administration, one might have greater accumulation of salicylate because of its prolonged halflife. 5 The latter therapy could be used in concert with the inhaled route or as stand-alone therapy in patient groups with low risk of systemic toxicity. Because of interindividual variability in metabolism, determination of plasma salicylate levels during repeated use would be important to avoid toxic blood levels. 1

ACE2 indicates angiotensin-converting enzyme receptor 2; ASA, acetylsalicylic acid; IκBα, inhibitor of NF-κB, IKK, IκB kinase; LASAG, D, L-lysine acetylsalicylate+glycine, NEMO, NF-κB essential modifier; P, phosphorylation; and SA, salicylate.

In summary, we acknowledge that our hypothesis would be strengthened if there were greater demonstration in animal models and humans that aspirin modulated the response to severe acute respiratory syndrome coronavirus 2. However, we believe that the evidence we present provides a rationale for further investigations of aspirin that are on our minds in this urgent time. The totality of evidence supports a potent viral inhibitory effect of ASA that is estimated at local millimolar concentrations. These concentrations should be achievable without major toxicity by inhalation. ASA has been our ally in the war of cardiovascular disease. The time is now to investigate the strength of our old friend in a new infectious disease war. 

Dr Gurbel reports grants and personal fees from Bayer HealthCare LLC, Janssen, and US WorldMeds LLC; personal fees from Otitopic Inc, Amgen, and UpTo-Date; and grants from Instrumentation Laboratory, Haemonetics, Medicure Inc, Idorsia Pharmaceuticals, and Hikari Dx. He is a consultant for Otitopic Inc, the company producing nanoparticle aspirin. In addition, Dr Gurbel has a patent, Detection of Restenosis Risk in Patients, issued and a patent, Assessment of Cardiac Health and Thrombotic Risk in a Patient. Dr Schrör received personal fees from Bayer. K.P. Bliden reports no conflicts.

L-lysine acetylsalicylate + glycine impairs coronavirus replication

Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients

First study of inhaled versus chewed aspirin: pharmacokinetic and pharmacodynamic effects. Paper presented at: ACC.20/WCC Congress of Cardiology

Dissolution and pharmacokinetics of a novel micronized aspirin formulation